Presence of pituitary adenylate cyclase activating polypeptide and its type I receptor in the rat kidney

Transplantation Proceedings

Volumn 43, Issue 4, 2011, Pages 1297-1299

  Brubel, R ^a   Horvath, G ^a   Reglodi, D ^a   Lubics, A ^a   Tamas, A ^a   Kiss, P ^a   Laszlo, E ^a   Nemeth, J ^c   Mark, L ^b   Szakaly, P ^b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1;

ANIMAL TISSUE; CELL PROTECTION; CONFERENCE PAPER; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY TUBULE CELL; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT;

ANIMALS; IMMUNOHISTOCHEMISTRY; KIDNEY; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 79957587817     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.03.081     Document Type: Conference Paper

References (14)

1. Vaudry D, Falluel-Morel A, Bourgault M, et al: Pituitary adenylate cyclase activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61:283, 2009
2. Sakuma Y, Ricordi C, Miki A, et al: Effect of pituitary adenylate cyclase activating polypeptide in islet transplantation. Transplant Proc 41:343, 2009
3. Szakaly P, Kiss P, Lubics A, et al: Effects of PACAP on survival and renal morphology in rats subjected to renal ischemia-reperfusion. J Mol Neurosci 36:89, 2008
4. Nilsson SF: PACAP-27 and PACAP-38: vascular effects in the eye and some other tissues in the rabbit. Eur J Pharmacol 253:17, 1994
5. Hautmann M, Friis UG, Desch M, et al: Pituitary adenylate cyclase activating polypeptide stimulates renin secretion via activation of PAC1 receptors. J Am Soc Nephrol 18:1150, 2007
6. Arimura A, Li M, Batuman V: Potential protective action of pituitary adenylate cyclase activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 107:661, 2006
7. Li M, Maderdrut JL, Lertora JJ, et al: Renoprotection by pituitary adenylate cyclase activating polypeptide in multiple myeloma and other kidney diseases. Regul Pept 145:24, 2008
8. Reubi JC: In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann NY Acad Sci 921:1, 2000
9. Peeters K, Gerets HH, Princen K, et al: Molecular cloning and expression of a chicken pituitary adenylate cyclase activating polypeptide receptor. Mol Brain Res 71:244, 1999
10. Borzsei R, Mark L, Tamas A, et al: Presence of pituitary adenylate cyclase activating polypeptide-38 in human plasma and milk. Eur J Endocrinol 160:561, 2009
11. Nemeth J, Jakab B, Jozsa R, et al: PACAP-27 radioimmunoassay: Description and application of a novel method. J Radioanal Nucl Chem 273:327, 2007
12. Steenstrup BR, Jorgensen JC, Alm P, et al: Pituitary adenylate cyclase activating polypeptide (PACAP): occurrence and vasodilatory effect in the human uteroplancetal unit. Regul Pept 61:197, 1996
13. Hannibal J, Ekblad E, Mulder H, et al: Pituitary adenylate cyclase activating polypeptide (PACAP) in the gastrointestinal tract of the rat: distribution and effects of capsaicin or denervation. Cell Tissue Res 291:65, 1998
14. Horváth G, Mark L, Brubel R, et al: Mice dificient in pituitary adenylate cyclase activating polypeptide display increased sensitivity to renal oxidative stress in vitro. Neurosci Lett 469:70, 2010